Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Jordi Codony‐Servat(Breast Cancer Research Foundation), Joan Albanell
Cited by 107
Related Papers
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
|British Journal of Cancer|2017|76
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
|Translational Lung Cancer Research|2019|17